title: [Expression of biomarkers related with bone marrow cells in patients with acute myelogenous leukemia].
abstract: This study was aimed to investigate the expression of biomarkers (PTEN, mTOR, NF-kB, CD44, PI3K) related with bone marrow cells in patients with acute myelogenous leukemia. The immunohistochemical method was used to detect the expression of PTEN, mTOR, NF-kB, CD44, PI3K in 20 patients. The AML patients were divided into remission group and non-remission group after calculating the percentage of leukemia cells in bone marrow. The results showed that by optical microscopy, the positive expression rates of PTEN, mTOR, NF-kB, CD44 and PI3K in remission group were 33.3%, 33.3%, 77.8%, 22.2%, 0, respectively; meanwhile, in non-remission group, the positive expression rates of above-menthioned biomarkers were 63.6%, 18.2, 90.9, 63.6%, 0, respectively. The percentage and mean OD for PTEN and CD44 were statistically different between the two groups (P < 0.05), but for mTOR, NF-kB and PI3K were not statistically differenly (P > 0.05). It is concluded that the high expression of PTEN and CD44 can be regarded as an important index for diagnosis and prognosis in acute myelogenous leukemia.
authors.affiliation: Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Huang
authors.affiliation: Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China; Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06520 USA.
authors.forename: Rong-Hua
authors.initials: RH
authors.lastname: Wang
authors.affiliation: Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China.
authors.forename: Dong-Yun
authors.initials: DY
authors.lastname: Li
authors.affiliation: Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China.
authors.forename: Zong-Lang
authors.initials: ZL
authors.lastname: Lai
authors.affiliation: Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China.
authors.forename: Yu-Ting
authors.initials: YT
authors.lastname: Chu
authors.affiliation: Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China; The Key Laboratory of Beijing and Ministry of Edncation (Traditional Chinses Internal Medicine), Beijing 100700, China. E-mail: chenxinyi0729@126.com.
authors.forename: Xin-Yi
authors.initials: XY
authors.lastname: Chen
mesh_terms: D015415:Biomarkers / Q000032:analysis; D001854:Bone Marrow Cells / Q000737:chemistry*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis; D016328:NF-kappa B; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D011379:Prognosis; D058570:TOR Serine-Threonine Kinases
chemical_list: D015415:Biomarkers; D016328:NF-kappa B; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human; C494929:PTEN protein, human